[HTML][HTML] Targeting EZH2 and PRC2 dependence as novel anticancer therapy
Distinctive patterns of chromatin modification control gene expression and define cellular
identity during development and cell differentiation. Polycomb repressive complex 2 (PRC2) …
identity during development and cell differentiation. Polycomb repressive complex 2 (PRC2) …
Multiple histone lysine methyltransferases are required for the establishment and maintenance of HIV-1 latency
We showed previously that the histone lysine methyltransferase (HKMT) H3K27me3 (EZH2)
is the catalytic subunit of Polycomb repressive complex 2 (PRC2) and is required for the …
is the catalytic subunit of Polycomb repressive complex 2 (PRC2) and is required for the …
Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic
Y Guo, R Cheng, Y Wang, ME Gonzalez, H Zhang… - …, 2024 - thelancet.com
The importance of EZH2 as a key methyltransferase has been well documented
theoretically. Practically, the first EZH2 inhibitor Tazemetostat (EPZ6438), was approved by …
theoretically. Practically, the first EZH2 inhibitor Tazemetostat (EPZ6438), was approved by …
Small molecule approaches for targeting the polycomb repressive complex 2 (PRC2) in cancer
The polycomb repressive complex 2 (PRC2) is composed of three core subunits, enhancer
of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 …
of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 …
Polycomb repressive complex 2 modulation through the development of EZH2–EED interaction inhibitors and EED binders
Epigenetics is nowadays a well-accepted area of research. In the last years, tremendous
progress was made regarding molecules targeting EZH2, directly or indirectly. Recently …
progress was made regarding molecules targeting EZH2, directly or indirectly. Recently …
MDM2 associates with polycomb repressor complex 2 and enhances stemness-promoting chromatin modifications independent of p53
M Wienken, A Dickmanns, A Nemajerova, D Kramer… - Molecular cell, 2016 - cell.com
The MDM2 oncoprotein ubiquitinates and antagonizes p53 but may also carry out p53-
independent functions. Here we report that MDM2 is required for the efficient generation of …
independent functions. Here we report that MDM2 is required for the efficient generation of …
Acetylation of VGLL4 regulates Hippo-YAP signaling and postnatal cardiac growth
Binding of the transcriptional co-activator YAP with the transcription factor TEAD stimulates
growth of the heart and other organs. YAP overexpression potently stimulates fetal …
growth of the heart and other organs. YAP overexpression potently stimulates fetal …
[HTML][HTML] Re-patterning of H3K27me3, H3K4me3 and DNA methylation during fibroblast conversion into induced cardiomyocytes
Direct conversion of fibroblasts into induced cardiomyocytes (iCMs) offers an alternative
strategy for cardiac disease modeling and regeneration. During iCM reprogramming, the …
strategy for cardiac disease modeling and regeneration. During iCM reprogramming, the …
EZH2 in cancer progression and potential application in cancer therapy: a friend or foe?
KS Yan, CY Lin, TW Liao, CM Peng, SC Lee… - International journal of …, 2017 - mdpi.com
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, catalyzes tri-methylation
of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic …
of histone H3 at Lys 27 (H3K27me3) to regulate gene expression through epigenetic …
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer
Y Bai, Z Zhang, L Cheng, R Wang, X Chen… - Journal of Biological …, 2019 - ASBMB
Enzalutamide, approved by the United States Food and Drug Administration in 2018 for the
management of metastatic castration-resistant prostate cancer (CRPC), is an androgen …
management of metastatic castration-resistant prostate cancer (CRPC), is an androgen …